敗血症(Sepsis):治療薬パイプラインレビュー

調査会社Global Markets Direct社が発行したリサーチレポート(データ管理コード:GMDHC10619IDB)
◆英語タイトル:Sepsis - Pipeline Review, H2 2018
◆発行会社/調査会社:Global Markets Direct
◆商品コード:GMDHC10619IDB
◆発行日:2018年7月17日
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆ページ数:278
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥228,000見積依頼/購入/質問フォーム
Site PriceUSD4,000 ⇒換算¥456,000見積依頼/購入/質問フォーム
Enterprise PriceUSD6,000 ⇒換算¥684,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[敗血症(Sepsis):治療薬パイプラインレビュー]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

Sepsis – Pipeline Review, H2 2018
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Sepsis – Pipeline Review, H2 2018, provides an overview of the Sepsis (Infectious Disease) pipeline landscape.

Sepsis is an illness in which the body has a severe response to bacteria or other germs. Sepsis occurs when chemicals released into the bloodstream to fight the infection trigger inflammation throughout the body. This response may be called systemic inflammatory response syndrome (SIRS). Symptoms of sepsis include chills, shaking, difficulty breathing, decrease in platelet count, abnormal heart pumping function and abdominal pain. The predisposing factors include age and weakened immune systems. Treatment includes antibiotics and vasopressor

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Sepsis – Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Sepsis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Sepsis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Sepsis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 9, 4, 2, 52, 8 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 23 and 2 molecules, respectively.

Sepsis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Sepsis (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Sepsis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Sepsis (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Sepsis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Sepsis (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Sepsis (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Sepsis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

*** レポート目次(コンテンツ)***

Table of Contents
Table of Contents 2
Introduction 5
Sepsis – Overview 6
Sepsis – Therapeutics Development 7
Sepsis – Therapeutics Assessment 22
Sepsis – Companies Involved in Therapeutics Development 32
Sepsis – Drug Profiles 50
Sepsis – Dormant Projects 249
Sepsis – Discontinued Products 255
Sepsis – Product Development Milestones 256
Appendix 266

List of Tables
Number of Products under Development for Sepsis, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Companies, H2 2018 (Contd..2), H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Companies, H2 2018 (Contd..2), H2 2018
Products under Development by Companies, H2 2018 (Contd..3), H2 2018
Products under Development by Companies, H2 2018 (Contd..4), H2 2018
Products under Development by Universities/Institutes, H2 2018
Products under Development by Universities/Institutes, H2 2018 (Contd..1), H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Target, H2 2018 (Contd..1), H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..1), H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Sepsis - Pipeline by Adrenomed AG, H2 2018
Sepsis - Pipeline by Am-Pharma BV, H2 2018
Sepsis - Pipeline by Arch Biopartners Inc, H2 2018
Sepsis - Pipeline by Asahi Kasei Corp, H2 2018
Sepsis - Pipeline by Atox Bio Ltd, H2 2018
Sepsis - Pipeline by Aurigene Discovery Technologies Ltd, H2 2018
Sepsis - Pipeline by Boehringer Ingelheim GmbH, H2 2018
Sepsis - Pipeline by Bristol-Myers Squibb Co, H2 2018
Sepsis - Pipeline by Cell2B Advanced Therapeutics SA, H2 2018
Sepsis - Pipeline by Cells for Cells SA, H2 2018
Sepsis - Pipeline by Chiome Bioscience Inc, H2 2018
Sepsis - Pipeline by Cilian AG, H2 2018
Sepsis - Pipeline by Cynata Therapeutics Ltd, H2 2018
Sepsis - Pipeline by CytaCoat AB, H2 2018
Sepsis - Pipeline by Dr. Franz Kohler Chemie GmbH, H2 2018
Sepsis - Pipeline by Endacea Inc, H2 2018
Sepsis - Pipeline by Enlivex Therapeutics Ltd, H2 2018
Sepsis - Pipeline by Evec Inc, H2 2018
Sepsis - Pipeline by Expression Drug Designs LLC, H2 2018
Sepsis - Pipeline by Immunwork Inc, H2 2018
Sepsis - Pipeline by InflaRx NV, H2 2018
Sepsis - Pipeline by Integrated BioTherapeutics Inc, H2 2018
Sepsis - Pipeline by Lead Discovery Center GmbH, H2 2018
Sepsis - Pipeline by Mochida Pharmaceutical Co Ltd, H2 2018
Sepsis - Pipeline by Nosopharm SAS, H2 2018
Sepsis - Pipeline by OncoImmune Inc, H2 2018
Sepsis - Pipeline by Ono Pharmaceutical Co Ltd, H2 2018
Sepsis - Pipeline by Opsona Therapeutics Ltd, H2 2018
Sepsis - Pipeline by ProThera Biologics Inc, H2 2018
Sepsis - Pipeline by Ra Pharmaceuticals Inc, H2 2018
Sepsis - Pipeline by Recce Ltd, H2 2018
Sepsis - Pipeline by Ribomic Inc, H2 2018
Sepsis - Pipeline by Rimonyx Pharmaceuticals Ltd, H2 2018
Sepsis - Pipeline by SciClone Pharmaceuticals Inc, H2 2018
Sepsis - Pipeline by SetLance srl, H2 2018
Sepsis - Pipeline by Shionogi & Co Ltd, H2 2018
Sepsis - Pipeline by Sirtex Medical Ltd, H2 2018
Sepsis - Pipeline by SK Biopharmaceuticals Co Ltd, H2 2018
Sepsis - Pipeline by Syntiron LLC, H2 2018
Sepsis - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018
Sepsis - Pipeline by Therakind Ltd, H2 2018
Sepsis - Pipeline by Therashock LLC, H2 2018
Sepsis - Pipeline by TiGenix NV, H2 2018
Sepsis - Pipeline by Vascular BioSciences, H2 2018
Sepsis - Dormant Projects, H2 2018
Sepsis - Dormant Projects, H2 2018 (Contd..1), H2 2018
Sepsis - Dormant Projects, H2 2018 (Contd..2), H2 2018
Sepsis - Dormant Projects, H2 2018 (Contd..3), H2 2018
Sepsis - Dormant Projects, H2 2018 (Contd..4), H2 2018
Sepsis - Discontinued Products, H2 2018

List of Figures
Number of Products under Development for Sepsis, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Top 10 Routes of Administration, H2 2018
Number of Products by Stage and Top 10 Routes of Administration, H2 2018
Number of Products by Top 10 Molecule Types, H2 2018
Number of Products by Stage and Top 10 Molecule Types, H2 2018

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
  • バラクタダイオードの世界市場:メーカー別、地域別、種類別、用途別、市場予測(~2022)
    Varactor Diodes also known as a variable capacitance diode, varicap diode or variable reactance diode, is a diode that has a variable capacitance which is a function of the voltage that is impressed on its terminals. Tuning / varactor diodes are operated reverse-biased, and therefore no current flow …
  • デジタル融資の世界市場2020-2025
    The retort pouch packaging market is expected to grow at a CAGR of 5.61% during the forecast period from 2020 to 2025. Moreover, the increasing demand for packed food is influencing the growth of this market. • Additionally, a higher number of consumers have shown a preference for on-the-go packagin …
  • 世界の背景抑制センサ市場2017
    Notes:Sales, means the sales volume of Background Suppression Sensor Revenue, means the sales value of Background Suppression Sensor This report studies sales (consumption) of Background Suppression Sensor in Global market, especially in United States, China, Europe and Japan, focuses on top players …
  • 世界及び中国の無水ピロメリト酸市場2017
    The 'Global and Chinese Pyromellitic Anhydride Industry, 2012-2022 Market Research Report' is a professional and in-depth study on the current state of the global Pyromellitic Anhydride industry with a focus on the Chinese market. The report provides key statistics on the market status of the Pyrome …
  • 副甲状腺機能低下症:治療薬開発パイプライン分析
    Hypoparathyroidism - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypoparathyroidism - Pipeline Review, H2 2017, provides an overview of the Hypoparathyroidism (Hormonal Disorders) pipeline landscape. Hypoparathyroidism is decre …
  • 世界の制汗剤市場2017
    Notes:Sales, means the sales volume of Antiperspirant Revenue, means the sales value of Antiperspirant This report studies sales (consumption) of Antiperspirant in Global market, especially in United States, China, Europe and Japan, focuses on top players in these regions/countries, with sales, pric …
  • 金属スタンピング(プレス加工)の世界市場
    ABSTRACTAbout Metal Stamping Stamping process involves placing a sheet of metal in a blank or coil form, where a tool or die surface gives the sheet a desired shape when subjected to pressure. Metals form an important component of many manufacturing and end-user industries. Industries such as the au …
  • 債務担保証券(CDO)の世界市場2016-2020
    About the Collateralized Debt Obligation (CDO) Market CDO refer to the securities that are packaged as one unit and serves as collateral for investors. The packaged assets comprise the corporate debt, mortgages, credit card, or automotive loans that are otherwise individual fixed income assets, whic …
  • 世界の胆道ステント市場:企業別、地域別、製品種類・用途別分析
    The global Biliary Stents market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. This report offers an overview of the market trends, drivers, and barriers with respect to the Biliary Stents market. It al …
  • 世界のフルベンジアミド市場予測 2020年-2025年
    According to this study, over the next five years the Flubendiamide market will register a xx% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies …
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(GMDHC10619IDB )"敗血症(Sepsis):治療薬パイプラインレビュー" (英文:Sepsis - Pipeline Review, H2 2018)はGlobal Markets Direct社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。